“Our rise reflects years of commitment to building a truly comprehensive cancer center where scientific discovery and exceptional patient care advance hand in hand,” said Stephen D. Nimer, M.D., director of Sylvester. He said the center’s multidisciplinary teams are increasingly equipped to deliver experimental therapies and specialized treatments to patients with complex or difficult-to-treat cancers. This model links laboratory research with clinical practice, allowing discoveries in areas such as tumor biology, molecular diagnostics and therapeutic development to move more efficiently toward patient care.

Sylvester is the only National Cancer Institute-designated cancer center in South Florida, a designation that recognizes institutions with substantial research activity, advanced cancer programs and a commitment to reducing the burden of cancer. Its work spans basic science, population research, clinical investigation and direct treatment. This integrated structure is designed to improve the accuracy of diagnosis, identify biological differences between tumors and match patients with therapies that are more precisely suited to the molecular characteristics of their disease.

A central component of that effort is Sylvester’s academic Phase 1 Clinical Trials Program, described as the only program of its kind in South Florida. Phase 1 trials are generally the first studies in which a new drug, biologic therapy or treatment combination is tested in people. Researchers primarily evaluate safety, tolerability, dosage and how the treatment behaves in the body, although early signals of effectiveness may also emerge. For patients whose cancers have resisted standard therapies, these studies can provide access to treatments years before they become broadly available, while generating data needed for later-stage clinical development.

The center’s research capacity expanded substantially with the opening of the 12-story Kenneth C. Griffin Cancer Research Building in 2025. The facility doubled Sylvester’s research space and brought scientists, physicians, clinical investigators and data specialists into closer proximity. Such physical and organizational integration is important in translational medicine, which seeks to convert discoveries from laboratory models into diagnostic tools, clinical trials and treatments. Shared research environments can accelerate the analysis of tumor samples, the testing of candidate therapies and the development of data-driven approaches to predicting treatment response.

Sylvester is also extending cancer research and prevention beyond its main clinical facilities. Its Game Changer mobile program brings cancer screening, education and research opportunities to medically underserved communities across South Florida. Mobile outreach can help reduce barriers related to transportation, geography and access to specialty care, while screening programs may identify disease at earlier and more treatable stages. The center also leads a nationally recognized firefighter cancer initiative focused on research, prevention, screening and advocacy, addressing occupational exposures and other factors that may influence cancer risk in firefighting populations.

Additional programs target cancer survivorship and prevention. An NCI-funded effort is working to strengthen survivorship care through community health centers, where patients may receive long-term monitoring and support closer to home after completing treatment. Sylvester is also advancing lifestyle medicine and research on human papillomavirus-associated cancers. HPV can contribute to the development of several malignancies, including cervical, anal, oropharyngeal and other cancers. Combining vaccination, screening, behavioral interventions and molecular research may help reduce preventable disease and improve outcomes for people already diagnosed.

The latest rankings reflect performance across the wider UHealth system as well. Four additional programs earned national rankings, including ophthalmology, neurology and neurosurgery, geriatrics, and cardiology, heart and vascular surgery. Bascom Palmer Eye Institute retained the nation’s No. 1 position in ophthalmology for the 25th consecutive year. UHealth’s neurology and neurosurgery program ranked No. 14 nationally and includes more than 70 research and clinical faculty working across neurological subspecialties. Five other specialties—urology, diabetes and endocrinology, gastroenterology and gastrointestinal surgery, orthopedics, and pulmonology and lung surgery—received high-performing designations, placing them among the top 10% of hospitals nationwide.

Together, the results point to an expanding health system built around specialized care, research infrastructure and long-term patient management. “We are proud of what these results say about our progress, but our focus remains on what comes next,” said Dipen J. Parekh, M.D., chief executive officer of UHealth. He said the system would continue investing in people, innovation and specialized services. For Sylvester, the national rise is both a measure of recent progress and a sign of the competitive importance of connecting advanced cancer biology, early-phase clinical research, community prevention and comprehensive care within a single academic health system.

Subject of Research: Cancer research, clinical oncology, cancer prevention, Phase 1 clinical trials and translational medicine.

Article Title: Sylvester Cancer Center Rises to No. 23 Nationwide in 2026 U.S. News Rankings

News Publication Date: August 4, 2026

Web References: Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center; Kenneth C. Griffin Cancer Research Building: https://umiamihealth.org/en/locations/sylvester-comprehensive-cancer-center-kenneth-c-griffin-cancer-research-building; UHealth rankings report: https://news.med.miami.edu/uhealth-highest-us-news-hospital-rankings-2026/

References: U.S. News & World Report 2026 Best Hospitals rankings; National Cancer Institute cancer center designation information; Sylvester Comprehensive Cancer Center announcement.

Image Credits: Sylvester Comprehensive Cancer Center

Keywords: Cancer, cancer research, clinical research, oncology, Phase 1 clinical trials, translational medicine, Sylvester Comprehensive Cancer Center, UHealth, University of Miami, National Cancer Institute, cancer prevention, survivorship care

Cancer care traditionally emphasizes diagnosis, treatment, and clinical management, but the multidimensional burdens patients endure are often underestimated. Unmet supportive care needs refer to the gaps in healthcare services and support systems that patients require but do not receive, encompassing physical, psychological, social, informational, and health system dimensions. Recognizing and quantifying these deficiencies is vital because they directly impact patient adherence to treatment, mental health status, and overall recovery trajectories.

The study adopted a rigorous cross-sectional design involving 260 cancer patients, reflecting a diverse representation across multiple cancer stages and demographic backgrounds. Employing a straightforward but effective random sampling methodology, the researchers meticulously collected data through validated instruments and ensured data integrity using advanced software tools such as EpiData and SPSS for thorough analysis. This methodological robustness strengthens the reliability of the findings and underscores the importance of data-driven decisions in oncology supportive care programming.

A striking finding from the research is the high prevalence of unmet supportive care needs, with nearly half of the respondents—45.9%—reporting at least one significant unmet need. This figure is both revealing and alarming, illustrating that existing healthcare structures are insufficient in meeting the holistic requirements of a substantial proportion of cancer patients. The pervasive nature of these unmet needs calls for urgent attention from healthcare providers, policymakers, and advocacy groups.

Among the spectrum of unmet needs identified, physical and health system needs emerged as the most prevalent. Physical needs encompass a range of symptoms and side effects related to cancer and its treatment, including pain, fatigue, and functional impairments, which often remain inadequately addressed. The prominence of health system needs points to systemic barriers such as accessibility, coordination of care, communication gaps, and resource limitations, which cumulatively hinder optimal patient support and satisfaction.

When diving deeper into the determinants of unmet supportive care needs, the analysis revealed that patient age, sex, educational attainment, and cancer stage at diagnosis are significant predictors. These factors illuminate the uneven distribution of support gaps and suggest targeted strategies to mitigate disparities. For instance, younger patients or those at advanced disease stages may require more intensive intervention efforts, while educational background could influence patients’ ability to seek help or navigate healthcare systems effectively.

The association between younger age and higher unmet needs might be interpreted through the lens of differing expectations and lifestyle impacts, as younger individuals often face unique challenges relating to employment, family roles, and psychosocial stressors. Gender differences in supportive care needs further complicate the landscape, possibly reflecting societal norms, communication patterns, and differential access to resources. Understanding these nuances is crucial for developing gender-sensitive and culturally appropriate care models.

Educational attainment serves as a proxy for health literacy and empowerment, influencing patients’ capacity to understand their illness, communicate effectively with providers, and advocate for necessary services. Lower educational levels may correlate with reduced awareness of available support options or hindered interactions with healthcare systems, exacerbating unmet needs. Therefore, patient education and navigation support should be integral components of care plans.

Cancer stage at diagnosis acts as an indicator of disease severity and complexity, with more advanced stages typically demanding comprehensive symptom management, palliative care, and psychosocial support. The study’s findings reinforce the necessity for stage-specific interventions, ensuring that patients at higher risk receive adequately tailored services that address their intensified needs.

This research is particularly critical in low-resource settings like Ethiopia, where healthcare infrastructure and supportive services face significant constraints. The insights gleaned demand not only clinical attention but also systemic reforms focusing on service delivery, workforce training, resource allocation, and policy frameworks that prioritize patient-centered care models. Addressing unmet supportive care needs is no longer a peripheral concern but a central pillar for improving cancer outcomes.

Moreover, the findings have broader implications for global oncology practice, highlighting universal challenges in supportive care delivery that transcend geographic and economic boundaries. They advocate for integrating comprehensive needs assessments into routine cancer care to identify gaps proactively and implement responsive interventions. Such integration requires multidisciplinary collaboration, technological innovation, and patient engagement strategies.

The study also exemplifies the role of rigorous quantitative research in unveiling complex healthcare issues. By employing logistic regression analyses, the researchers could isolate and quantify the impact of multiple variables simultaneously, providing a nuanced understanding of the interplay between demographic and clinical factors. This analytical approach strengthens the evidence base necessary for targeted program development.

Future directions prompted by this research include the development of culturally sensitive assessment tools, scalable supportive care interventions, and health policy reforms that embed supportive care as an essential component of cancer management. Education of healthcare providers about the importance of recognizing and responding to supportive care needs is equally vital to translating research into practice.

In addition to addressing physical symptoms, psychosocial support, information dissemination, and coordination of care should be prioritized. These dimensions are interrelated and collectively contribute to alleviating the burden experienced by cancer patients. Tailored interventions that respect patient preferences, cultural contexts, and local healthcare realities stand the best chance of success.

Technological advancements such as telemedicine, digital health platforms, and mobile health applications can also be leveraged to bridge the gaps in supportive care, especially in underserved areas. Innovative solutions might enhance communication, follow-up, and resource accessibility, thereby reducing unmet needs efficiently and cost-effectively.

In conclusion, the research underscores a pressing, yet often overlooked, facet of cancer care—the unmet supportive care needs that compromise patient well-being and treatment efficacy. By illuminating the scope and determinants of these needs among Ethiopian cancer patients, the study paves the way for informed interventions and policy measures aimed at optimizing supportive care delivery. The ultimate goal is to transform cancer care into a truly holistic endeavor that empowers patients, supports recovery, and enhances quality of life across all stages of the disease.

Subject of Research: Unmet supportive care needs and associated factors among cancer patients

Article Title: Unmet supportive care need and associated factors among cancer patients

Article References:
Mehari, W.D., Sun, Y., Lei, Y. et al. Unmet supportive care need and associated factors among cancer patients.
BMC Cancer 25, 1260 (2025). https://doi.org/10.1186/s12885-025-14607-w

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14607-w

Foremost among the recent discoveries is a novel combination drug therapy designed specifically for advanced melanoma patients harboring mutations in the BRAF gene. BRAF, a critical regulator of cell division, when mutated, drives unchecked proliferation characteristic of aggressive melanomas. The research team led by Sheri Holmen, PhD, has targeted this oncogenic pathway by employing a multi-pronged inhibition strategy encompassing Focal Adhesion Kinase (FAK), RAF, and MEK enzymes. FAK, a tyrosine kinase implicated in tumor cell migration and survival, was inhibited alongside established RAF and MEK inhibitors, which are integral components of current melanoma standard of care. Preclinical murine models demonstrated that this synergistic blockade not only significantly prolonged survival but also effectively prevented metastasis to the brain—a prevalent and devastating complication in melanoma progression.

The implications of these findings are profound, considering that the Mountain West region exhibits one of the highest melanoma incidence rates nationally. Brain metastasis remains a critical hurdle, often portending poor prognoses and limited therapeutic options. By halting metastatic dissemination to the central nervous system, this therapeutic combination holds promise to redefine the clinical management paradigm for advanced melanoma. Building on these promising preclinical results, early-phase clinical trials at HCI and the Holden Comprehensive Cancer Center at the University of Iowa have commenced, exploring the efficacy and safety profiles of this drug cocktail. This clinical investigation is spearheaded by Howard Colman, MD, PhD, who brings extensive expertise in neurosurgical oncology to the trial framework.

Beyond pharmacologic innovations, the incorporation of personalized exercise programs into cancer care is emerging as a pivotal adjunct therapy to improve clinical outcomes. Two influential studies from HCI underscore the measurable benefits of precision-tailored exercise interventions within lung and breast cancer patient cohorts. The Precision Exercise Prescription (PEP) trial enrolled 182 individuals diagnosed with primary lung cancer or lung metastases, randomizing participants to receive either a remotely monitored, customized exercise regimen initiated two weeks prior to and following surgical interventions, or standard postoperative care devoid of such intervention. Results revealed striking preservation and, in some cases, enhancement of physical function among those engaged in the exercise program, contrasted with significant functional declines observed in the control group.

This research conveys a paradigm shift—underscoring exercise not as an ancillary or optional supportive measure but as an indispensable therapeutic modality to alleviate postoperative morbidity and fatigue. Neli Ulrich, PhD, MS, underscores the critical nature of these findings, particularly the gender-specific improvements observed among women, advocating for widespread integration of individualized exercise regimens into oncologic treatment protocols. Furthermore, Thomas Varghese Jr., MD, MS, MBA, FACS, highlights the capacity of remote delivery platforms to democratize access to rehabilitative care, especially benefiting patients residing in rural or medically underserved geographies.

Complementing these insights, the Comprehensive Oncology Rehabilitation and Exercise (CORE) trial, led by Adriana Coletta, PhD, further elucidates the feasibility and clinical utility of structured exercise algorithms in newly diagnosed breast cancer patients. Employing a randomized controlled design, the study actively evaluated an algorithmic workflow intended to seamlessly embed exercise prescription into routine clinical management. The observed enhancements in patient-reported physical activity levels and functional outcomes reinforce the growing evidentiary consensus that rehabilitation-oriented strategies must be systematically incorporated within multidisciplinary cancer care frameworks.

The innovations at Huntsman Cancer Institute extend into hematologic oncology through a pioneering allogeneic stem cell transplantation approach utilizing grafts derived from deceased donors. Traditionally, allogeneic stem cell transplantation relies on matched living donors, a constraint that severely limits patient access and prolongs wait times for those with aggressive blood cancers such as acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, and non-Hodgkin lymphoma. This groundbreaking method, led by Sagar Patel, MD, involves harvesting hematopoietic stem cells from the vertebral columns of deceased organ donors who had consented to donation. The approach leverages organ donor registries to create an expanded, banked resource of stem cell grafts, potentially revolutionizing transplant availability and clinical logistics.

As a Phase 1 clinical trial progresses under the aegis of the Biomedical Advanced Research and Development Authority with collaboration from Ossium Health, the transplant community eagerly anticipates data reifying the safety and efficacy of this novel graft source. Success in this domain promises to substantially broaden therapeutic opportunities, expedite transplantation timelines, and ultimately improve survival outcomes for patients confronting hematologic malignancies.

These transformative achievements within basic science, translational research, and clinical application exemplify Huntsman Cancer Institute’s commitment to revolutionizing cancer care. Supported by an extensive portfolio of over 325 active clinical trials and more than 275 dedicated research teams, HCI continues to pioneer oncologic discovery and therapeutic innovation. Its status as a regional beacon for cancer research and treatment encompasses a multi-state catchment area including Utah, Idaho, Montana, Nevada, and Wyoming, addressing pressing public health challenges through precision medicine and comprehensive patient-centered care.

Additionally, the institute celebrates recent recognition of its faculty excellence, including Bruce Edgar, PhD’s election to the National Academy of Sciences—validating the caliber of scientific leadership driving cancer research innovations at HCI.

Collectively, these breakthroughs underscore a new era in oncology wherein molecularly targeted drug combinations, rehabilitative exercise protocols, and cutting-edge transplantation methodologies converge to redefine survivorship and disease control. As these clinical and translational advances move forward, they offer tangible hope for patients confronting some of the most formidable forms of cancer, cementing Huntsman Cancer Institute’s role at the forefront of cancer innovation.

Subject of Research: Advanced melanoma treatments, precision exercise in cancer recovery, allogeneic stem cell transplantation from deceased donors, clinical oncology innovations

Article Title: Groundbreaking Advances at Huntsman Cancer Institute Propel Cancer Treatment and Recovery

Web References:

• Huntsman Cancer Institute
• Sheri Holmen, PhD Lab
• Clinical trial NCT06194929
• Cell Reports Medicine article
• Precision Exercise Prescription (PEP)
• CORE trial publication
• Blood and Marrow Transplant program
• NCT05589896 Phase 1 trial

Image Credits: Credit: Huntsman Cancer Institute

Keywords: Cancer research, targeted therapy, melanoma, brain metastasis prevention, BRAF mutation, FAK inhibition, precision exercise prescription, lung cancer recovery, breast cancer rehabilitation, allogeneic stem cell transplant, deceased donor grafts, hematologic malignancies, clinical trials